Jenn Abelin, Ph.D.
Senior Group Leader
Jenn Abelin is a senior group leader in the Proteomics Platform at the Ó³»´«Ã½ of MIT and Harvard and an affiliated researcher of Dana-Farber Cancer Institute’s Translational Immunogenomics Lab (TIGL). Abelin leads a multi-disciplinary team of researchers who work closely with their collaborators to develop and apply mass spectrometry-based immunopeptidomics to identify peptides displayed to T cells by HLA-I and HLA-II cell surface molecules, which play a major role in adaptive immune responses. Immunopeptidomics enables a deeper understanding of antigen processing and presentation and allows the direct identification of disease specific HLA-I and HLA-II bound peptides, which are potential therapeutic targets.
Prior to rejoining the Ó³»´«Ã½ at the end of 2019, Abelin established and led the immunopeptidomics group at the biotech Neon Therapeutics from 2016 to 2019. From 2013 to 2016, Abelin was a postdoctoral fellow in the Proteomics Platform. She is also a recipient of a Merkin Institute Fellowship at the Ó³»´«Ã½ in 2025.
Abelin received her B.Sc. from Guilford College in biology and chemistry (2009) and her Ph.D. from the University of Virginia (2012).
February 2025
